Literature DB >> 15626455

Cardioprotective effects of glyceryl trinitrate: beyond vascular nitrate tolerance.

Tamás Csont1, Péter Ferdinandy.   

Abstract

Organic nitrates have been used for the treatment of ischemic heart diseases for more than 100 years and these drugs are still amongst the most frequently prescribed and applied drugs worldwide. Development of tolerance against the hemodynamic effects of nitrates during sustained therapy, however, limits their clinical application. Moreover, recent clinical studies have suggested that long-term nitrate treatment does not improve or may even worsen cardiovascular mortality, possibly due to the development of vascular nitrate tolerance. In agreement with these clinical findings, nitrate tolerance has been shown to increase superoxide and peroxynitrite production leading to vascular dysfunction. Nevertheless, nitrates exert a direct myocardial anti-ischemic effect that is independent from their vascular actions. The direct myocardial effect of glyceryl trinitrate (GTN) has been shown to be preserved even in the state of vascular nitrate tolerance. Moreover, no oxidative stress was observed in hearts isolated from rats with vascular nitrate tolerance, while increased systemic peroxynitrite formation was detected in the plasma in the same animals. The different effects of nitrates on the heart and vasculature are not well characterized; however, tissue specific differences in the metabolism and cellular signaling of nitrates might be a plausible explanation. These data suggest that sustained nitrate treatment increases oxidative stress in the extracardiac vasculature, thereby promoting the development of vascular nitrate tolerance. However, the direct myocardial anti-ischemic effect of nitrates seems to be preserved beyond the development of vascular nitrate tolerance. These new findings may open new perspectives in the clinical use of organic nitrates and suggest that the development of either cardioselective nitrates or nitrate-antioxidant hybrid drugs may replace classical nitrates in the therapy of ischemic heart disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15626455     DOI: 10.1016/j.pharmthera.2004.10.001

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  18 in total

Review 1.  Nitroglycerin use in myocardial infarction patients.

Authors:  Julio C B Ferreira; Daria Mochly-Rosen
Journal:  Circ J       Date:  2011-11-01       Impact factor: 2.993

Review 2.  Headache-type adverse effects of NO donors: vasodilation and beyond.

Authors:  G Bagdy; P Riba; V Kecskeméti; D Chase; G Juhász
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

3.  Vitamin C: new role of the old vitamin in the cardiovascular system?

Authors:  Csaba Kónya; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

4.  Ca2+-mediated ascorbate release from coronary artery endothelial cells.

Authors:  Kim A Davis; Sue E Samson; Kelly Best; Kanwaldeep K Mallhi; Magdalena Szewczyk; John X Wilson; Chiu-Yin Kwan; Ashok K Grover
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 5.  The role of gasotransmitters NO, H2S and CO in myocardial ischaemia/reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning.

Authors:  Ioanna Andreadou; Efstathios K Iliodromitis; Tienush Rassaf; Rainer Schulz; Andreas Papapetropoulos; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2014-09-23       Impact factor: 8.739

Review 6.  Cardiac NO signalling in the metabolic syndrome.

Authors:  O Pechánová; Z V Varga; M Cebová; Z Giricz; P Pacher; P Ferdinandy
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

7.  Role of cGMP-dependent protein kinase in development of tolerance to nitroglycerine in porcine coronary arteries.

Authors:  D Dou; X Zheng; X Qin; H Qi; L Liu; J U Raj; Y Gao
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

Review 8.  Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling.

Authors:  D S Burley; P Ferdinandy; G F Baxter
Journal:  Br J Pharmacol       Date:  2007-08-13       Impact factor: 8.739

9.  O2-acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO-NSAIDs): synthesis, nitric oxide release, and biological evaluation studies.

Authors:  Carlos A Velázquez; P N Praveen Rao; Michael L Citro; Larry K Keefer; Edward E Knaus
Journal:  Bioorg Med Chem       Date:  2007-05-06       Impact factor: 3.641

10.  Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Prodrugs as Drug Candidates for the Treatment of Ischemic Disorders: Insights into NO-Releasing Prodrug Biotransformation and Hemoglobin-NO Biochemistry.

Authors:  Guoyan G Xu; Tanvi M Deshpande; Mohini S Ghatge; Akul Y Mehta; Abdel Sattar M Omar; Mostafa H Ahmed; Jurgen Venitz; Osheiza Abdulmalik; Yan Zhang; Martin K Safo
Journal:  Biochemistry       Date:  2015-12-03       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.